661 related articles for article (PubMed ID: 9745404)
1. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
[TBL] [Abstract][Full Text] [Related]
2. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
[TBL] [Abstract][Full Text] [Related]
3. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.
Van den Berghe G; de Zegher F; Bowers CY; Wouters P; Muller P; Soetens F; Vlasselaers D; Schetz M; Verwaest C; Lauwers P; Bouillon R
Clin Endocrinol (Oxf); 1996 Sep; 45(3):341-51. PubMed ID: 8949573
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.
Van den Berghe G; de Zegher F; Baxter RC; Veldhuis JD; Wouters P; Schetz M; Verwaest C; Van der Vorst E; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1998 Feb; 83(2):309-19. PubMed ID: 9467533
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness.
Van den Berghe G; Wouters P; Weekers F; Mohan S; Baxter RC; Veldhuis JD; Bowers CY; Bouillon R
J Clin Endocrinol Metab; 1999 Apr; 84(4):1311-23. PubMed ID: 10199772
[TBL] [Abstract][Full Text] [Related]
6. Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Gouwy S; Stockman W; Weekers F; Schetz M; Lauwers P; Bouillon R; Bowers CY
Clin Endocrinol (Oxf); 1997 Nov; 47(5):599-612. PubMed ID: 9425400
[TBL] [Abstract][Full Text] [Related]
7. A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness.
Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 2000 Jan; 85(1):183-92. PubMed ID: 10634385
[TBL] [Abstract][Full Text] [Related]
8. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.
Van den Berghe G; Baxter RC; Weekers F; Wouters P; Bowers CY; Iranmanesh A; Veldhuis JD; Bouillon R
Clin Endocrinol (Oxf); 2002 May; 56(5):655-69. PubMed ID: 12030918
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone secretagogues in critical illness.
Van den Berghe G
Horm Res; 1999; 51 Suppl 3():21-8. PubMed ID: 10592440
[TBL] [Abstract][Full Text] [Related]
10. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness.
van den Berghe G; Weekers F; Baxter RC; Wouters P; Iranmanesh A; Bouillon R; Veldhuis JD
J Clin Endocrinol Metab; 2001 Jul; 86(7):3217-26. PubMed ID: 11443192
[TBL] [Abstract][Full Text] [Related]
11. Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women.
Bowers CY; Granda R; Mohan S; Kuipers J; Baylink D; Veldhuis JD
J Clin Endocrinol Metab; 2004 May; 89(5):2290-300. PubMed ID: 15126555
[TBL] [Abstract][Full Text] [Related]
12. Tissue deiodinase activity during prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone-releasing peptide-2.
Debaveye Y; Ellger B; Mebis L; Van Herck E; Coopmans W; Darras V; Van den Berghe G
Endocrinology; 2005 Dec; 146(12):5604-11. PubMed ID: 16150898
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.
Van den Berghe G; Wouters P; Bowers CY; de Zegher F; Bouillon R; Veldhuis JD
Eur J Endocrinol; 1999 Jan; 140(1):17-22. PubMed ID: 10037246
[TBL] [Abstract][Full Text] [Related]
14. Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness.
Weekers F; Michalaki M; Coopmans W; Van Herck E; Veldhuis JD; Darras VM; Van den Berghe G
Endocrinology; 2004 Jan; 145(1):205-13. PubMed ID: 14551231
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
[TBL] [Abstract][Full Text] [Related]
16. Tripartite neuroendocrine activation of the human growth hormone (GH) axis in women by continuous 24-hour GH-releasing peptide infusion: pulsatile, entropic, and nyctohemeral mechanisms.
Shah N; Evans WS; Bowers CY; Veldhuis JD
J Clin Endocrinol Metab; 1999 Jun; 84(6):2140-50. PubMed ID: 10372723
[TBL] [Abstract][Full Text] [Related]
17. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus.
Huhn WC; Hartman ML; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1993 May; 76(5):1202-8. PubMed ID: 8496311
[TBL] [Abstract][Full Text] [Related]
18. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.
Jaffe CA; Ho PJ; Demott-Friberg R; Bowers CY; Barkan AL
J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313
[TBL] [Abstract][Full Text] [Related]
19. Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion.
Muller AF; Janssen JA; Lamberts SW; Bidlingmaier M; Strasburger CJ; Hofland L; van der Lely AJ
Clin Endocrinol (Oxf); 2001 Oct; 55(4):461-7. PubMed ID: 11678828
[TBL] [Abstract][Full Text] [Related]
20. The impact of cranial irradiation on GH responsiveness to GHRH plus GH-releasing peptide-6.
Popovic V; Pekic S; Golubicic I; Doknic M; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 2002 May; 87(5):2095-9. PubMed ID: 11994347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
